Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YDNCM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Rit-v1a-145-PF01
|
|||||
| Synonyms |
rit-v1a-145-PF01
Click to Show/Hide
|
|||||
| Organization |
SYNAFFIX B.V.
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
BCN-rituximab rit-v1a-145
|
Antibody Info | ||||
| Antigen Name |
T-cell surface glycoprotein CD3 (CD3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
DBCO-Azide Click Chemistry Conjugation
|
|||||
| Combination Type |
HOKT3-PEG11-tetrazine PF01
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
100.3 pM
|
|||
| Method Description |
The bispecific effect of hOKT3200 on human PBMC killing RajiB tumor cells. The bispecific and calculated EC50 values are shown in the legend.
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||